Gene "CBS"
Found 2 records
Gene information
Gene symbol:
CBS
See related:
Ensembl: ENSG00000160200, Gene ID: 102724560
Additive variants :
Detected
Genetic interaction partners
Confidence      Stringent (ε>0.16 or ε<-0.12)      Intermediate (-0.16≤ε≤-0.08 or 0.08≤ε≤0.16)      Lenient (|ε|<0.08)
Positive interactions
  • BUD31 
  • RPSA 
  • ELOVL1 
  • ACAA1 
  • MAP3K2 
  • DICER1 
  • EEF1G 
  • EIF2B1 
  • FOXD3 
  • ABHD2 
  • ZDHHC4 
  • OGFOD1 
  • SNX2 
  • MAST2 
  • SLC32A1 
  • ERCC1 
  • STRIP2 
  • PUS7L 
  • H3F3C 
  • SLC3A1 
  • DNM1L 
  • DOT1L 
  • NIT2 
  • CLK2 
  • SFN 
  • GPX7 
  • PRDX6 
  • NF1 
  • CHIA 
  • PHGDH 
  • COX6B2 
  • GPX7 
  • TMED10 
  • SIRT2 
  • RRM1 
  • PAPSS1 
  • SLC47A2 
  • BRSK1 
  • SLC38A7 
  • NAPEPLD 
  • TGIF2 
  • HHATL 
  • ADI1 
  • KDM4A 
  • PAQR3 
  • DPH6 
  • SFXN1 
  • MEF2A 
  • NKTR 
  • METTL2A 
  • CYB5RL 
  • PRELID3A 
Negative interactions
  • TGFBRAP1 
  • ADA 
  • VPS13D 
  • VPS41 
  • HDAC7 
  • ADAP2 
  • UBE2D3 
  • HGS 
  • H2AFX 
  • USP13 
  • MPC1 
  • UBE2V2 
  • SERINC2 
  • KATNA1 
  • PEX5L 
  • RAB7A 
  • CHMP3 
  • RPLP2 
  • RPS11 
  • STAM2 
  • DRG1 
  • RTN4IP1 
  • MSH3 
  • EGR3 
  • SAC3D1 
  • CNDP1 
  • BIN3 
  • TSR3 
  • RCOR1 
  • SFT2D3 
  • NFXL1 
  • PPAT 
  • CLPX 
  • WDR59 
  • RPS24 
  • CDC73 
  • RPL13A 
  • PDHA2 
  • AIRE 
  • PPAN 
  • ZFP42 
  • PGRMC2 
  • VAT1L 
  • GCLC 
  • SHMT2 
  • PLAA 
  • FAU 
  • GATA2 
  • PSD3 
  • USP17L30 
  • XPNPEP2 
  • ELOF1 
  • RPL29 
  • TBC1D22A 
  • TTC37 
  • SLC11A2 
  • CNNM2 
  • RPL9 
  • RAD51 
  • RPL9 
  • RPS16 
  • PQLC2L 
  • ATAD2 
  • KMO 
  • PGLS 
  • DCUN1D5 
  • RPS7 
  • RPL38 
  • GSS 
  • RANGRF 
  • EDF1 
  • WDR6 
  • DPH7 
  • FKBP15 
  • RPLP2 
  • DHODH 
  • PEX1 
  • RPL37 
  • AGPAT4 
  • GLRX3 
  • DDX59 
  • PTRH2 
  • ABCC5 
  • MPC2 
  • RPL13 
  • HAO2 
  • HHATL 
  • TXNDC9 
  • TXNL1 
  • NCBP2 
  • CCNA2 
  • RPS10 
  • PIAS1 
  • CS 
  • CLIP1 
  • MTHFR 
  • MYO15B 
  • SOD2 
  • ALG6 
  • IDH3A 
  • RPS29 
  • PRDX1 
  • UCK2 
  • ALG12 
  • HEMK1 
  • PNPLA6 
  • KIFC2 
  • GDA 
  • PSMD4 
  • SLC25A44 
  • PGGHG 
  • LENG8 
Modifier statisitcs
Record:
Disorder:
Vriant:
Reference:
Effect type:
Expressivity(1) ,Penetrance(1)  
Modifier effect:
Altered incidence(1) ,Altered severity(1)  
Details:
  • Variant 1:
    Gene:
    Genomic location:
    dbSNP ID:
    Target disease:
    Effect type:
    Penetrance 
    Modifier effect:
    Altered incidence 
    Evidence:
    P=0.001 
    Effect:
    The cystathionine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy.
    Reference:
    Title:
    The cystathionine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy.
    Species studied:
    Human
    Abstract:
    The clinical course of X-linked adrenoleukodystrophy (X-ALD) is of unexplained heterogeneity. Major X-ALD phenotypes are the progressive childhood cerebral form (CCALD) with early confluent cerebral demyelination and the adult-onset adrenomyeloneuropathy (AMN). Adult AMN may present with demyelinated foci of the CNS (adrenoleukomyeloneuropathy, ALMN) or without (pure AMN). Activated methionine is essential for CNS myelination, and methionine metabolism is important for glutathione synthesis, which may influence neurodegeneration. Cystathionine beta-synthase (CBS) is a key enzyme of methionine metabolism. The CBS variant c.844_845ins68 (p.-) may influence the availability of activated methionine as well as of glutathione. In this study, we analyzed this variant in genomic DNA samples of 86 X-ALD patients. We observed the allele carrying the insertion in 12 of 49 patients without CNS demyelination (pure AMN), but in none of the 37 patients with CNS demyelination (CCALD or ALMN; chi(2)=10.531; p=0.001). We conclude that the insertion allele of CBS c.844_845ins68 protected X-ALD patients against CNS demyelination in our study sample. These data suggest that the individual conditions in methionine metabolism may be a disease modifier of X-ALD. Since methionine metabolism can easily be influenced by vitamin and amino acid substitution, this observation could be a basis of novel treatment strategies in this yet untreatable disease. (c) 2006 Wiley-Liss, Inc.
  • Gene:
    Genomic location:
    chr21:44492158
    dbSNP ID:
    Target disease:
    Effect type:
    Expressivity 
    Modifier effect:
    Altered severity 
    Evidence:
    Pedigree analysis and gene activity study 
    Effect:
    Genetic modifiers of TAA severity
    Reference:
    Title:
    Exome Sequencing Identifies Candidate Genetic Modifiers of Syndromic and Familial Thoracic Aortic Aneurysm Severity.
    Species studied:
    Human
    Abstract:
    Thoracic aortic aneurysm (TAA) is a genetic disease predisposing to aortic dissection. It is important to identify the genetic modifiers controlling penetrance and expressivity to improve clinical prognostication. Exome sequencing was performed in 27 subjects with syndromic or familial TAA presenting with extreme phenotypes (15 with severe TAA; 12 with mild or absent TAA). Family-based analysis of a subset of the cohort identified variants, genes, and pathways segregating with TAA severity among three families. A rare missense variant in ADCK4 (p.Arg63Trp) segregated with mild TAA in each family. Genes and pathways identified in families were further investigated in the entire cohort using the optimal unified sequence kernel association test, finding significance for the gene COL15A1 (p = 0.025) and the retina homeostasis pathway (p = 0.035). Thus, we identified candidate genetic modifiers of TAA severity by exome-based study of extreme phenotypes, which may lead to improved risk stratification and development of new medical therapies.